Aerocrine, Circassia deal

Circassia will acquire Aerocrine for SEK2.55 per share, or about SEK1.8 billion ($215.1 million) in cash. The price is an 18% premium to Aerocrine’s close of SEK2.17 on May 14, the day before the deal was announced. Circassia said the acquisition would add to its sales force in the U.S. and Europe ahead of its anticipated approval and launch of Cat-SPIRE, a T cell vaccine that uses ToleroMune T cell epitope desensitization technology to treat cat allergies. ...